Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)Elizabeth Dudnik, Nir Peled, Anna Belilovski Rozenblum et al.|Lung Cancer|2018Cited by 75